First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy - Wikidata - awgldk - TriplyDB

First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy

First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy

http://www.wikidata.org/entity/Q28071522

about

Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP Exome Sequencing and Gene Prioritization Correct Misdiagnosis in a Chinese Kindred with Familial Amyloid Polyneuropathy New technologies for the assessment of neuropathies.The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market.Transthyretin familial amyloid polyneuropathy (TTR-FAP) in Mallorca: a comparison between late- and early-onset disease.Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy.Autonomic Neuropathy and Albuminocytologic Dissociation in Cerebrospinal Fluid As the Presenting Features of Primary Amyloidosis: A Case Report.Update on the clinical utility of an RNA interference-based treatment: focus on Patisiran.Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm.Cardiac and peripheral vasomotor autonomic functions in late-onset transthyretin Val30Met familial amyloid polyneuropathy.A novel ATTR L32V mutation causes familial amyloid polyneuropathy in a Bolivian family.Minor salivary gland biopsy for the diagnosis of familial amyloid polyneuropathy.Positive Effectiveness of Tafamidis in Delaying Disease Progression in Transthyretin Familial Amyloid Polyneuropathy up to 2 Years: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS).Transthyretin familial amyloid polyneuropathy (TTR-FAP): Parameters for early diagnosis.From older to younger: intergenerational promotion of health behaviours in Portuguese families affected by familial amyloid polyneuropathy.Small Fiber Neuropathy: Disease Classification Beyond Pain and Burning.Amyloidosis due to TTR mutations in Mexico with 4 distincts genotypes in the index cases.Promoção da saúde em famílias com paramiloidose: papéis dos mais velhos junto dos mais novos

P2860

Q28076550-308B2763-381E-479A-8577-E5116C0C1A2C Q28078350-0FEC4069-3C4A-412B-A481-27124518003D Q36925525-2D08C206-A1EC-4B72-89AF-65EAE398DB60 Q38743705-DC1A504D-0B6D-4093-AC7D-C04898988BCC Q39227810-42D66449-2597-4CAA-9EB4-92199EFAC669 Q39610783-330D3B2B-BB76-45E1-A425-CB746E414700 Q40166313-E9C05E39-EE17-40C1-A39A-E7C790A4D995 Q41123192-00BEC8C1-AD8E-45AB-84C8-8204C993C2A3 Q47106501-031CC925-B755-4FA3-BCA8-DA966D53DB33 Q47561760-F1B3D91F-8CE8-4E94-879E-DC8185CC89DF Q49567725-F5A6DCA7-E688-481A-9BA8-02AEE33BC115 Q50926282-CF8CCC37-66F4-44CF-BB90-02D91FD84603 Q51325406-14415E03-0150-4CA8-9EF7-D052E6FFBE85 Q52597244-C754E5E6-48B3-4D53-9DE5-18356D0E7F3A Q55280701-DB16508A-DB0E-479E-B1D8-9D97C0DF8977 Q55288738-1F67B0EA-69B2-4B09-82A8-D628ABD872DA Q55310742-F9210475-7986-49A0-86D8-11A958F52DCA Q55496479-D5D7660E-5389-410B-A281-55883D53043A Q58427652-133DDF4C-800F-432A-81B4-CCB8101FBDE7

P2860

First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy

http://www.wikidata.org/entity/Q28071522

description

2016 nî lūn-bûn

@nan

2016 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

First European consensus for d ...... amilial amyloid polyneuropathy

@ast

First European consensus for d ...... amilial amyloid polyneuropathy

@en

First European consensus for d ...... amilial amyloid polyneuropathy

@nl

type

label

First European consensus for d ...... amilial amyloid polyneuropathy

@ast

First European consensus for d ...... amilial amyloid polyneuropathy

@en

First European consensus for d ...... amilial amyloid polyneuropathy

@nl

prefLabel

First European consensus for d ...... amilial amyloid polyneuropathy

@ast

First European consensus for d ...... amilial amyloid polyneuropathy

@en

First European consensus for d ...... amilial amyloid polyneuropathy

@nl

P1433

Q28071522-51BF9A84-E47B-44E4-A5F3-365BE167C356

P1476

Q28071522-79DCA231-70BA-4F68-89A6-2EA9533B7D54

P2093

Q28071522-0240FA59-8AE5-4D17-ACE3-88C71D7CDEAB

Q28071522-07A1DDA1-1AC9-4009-A1CB-AC8E256DE3C1

Q28071522-33932277-12CF-4AD6-BFAF-A167F379E1FD

Q28071522-543B6EAA-B86D-47B0-B378-246E105168E1

Q28071522-9AFC9A4F-C199-4B68-B100-54613A1B745A

Q28071522-B796183B-A1F8-4870-B845-AE1E8F8C62C6

Q28071522-C3AEFEA6-9D18-4AE9-BF3F-A76DFF2AE4DF

P275

Q28071522-09B6759D-7E86-46CF-BE06-4A3D9BE3EBA9

P2860

Q28071522-0037A5E2-0E29-4453-8971-AA12E0FAC54B

Q28071522-0232355B-A487-4E42-BDEA-55E1E794A813

Q28071522-041ECC73-C536-4653-B404-8F7F8548E6F8

Q28071522-06CA6BDC-B543-48CB-B5A8-5238ED258B71

Q28071522-0BCE4FFF-BFEF-4BAD-88E4-3537B93A7E1F

Q28071522-0C47CA52-FD57-486E-A13A-E69B2CE4F2EB

Q28071522-0DE509B7-2897-4ABA-B17B-EBE3AB4FFF34

Q28071522-0F29EA32-22FD-4013-9A6E-B9FBE146A842

Q28071522-10B64A32-6CD6-479A-80EB-5DDE73DA7DF1

Q28071522-18C75799-6BA2-4A6E-9F09-1B721C579B05

P304

Q28071522-FF06BE3B-7DC6-46D7-A697-BCB0C1113E69

P31

Q28071522-FD6068C5-7A76-4B22-8AFF-E1BF9340243E

P3181

Q28071522-7ADA2AB4-6C9F-4762-B7AA-36F6CB583A0C

P356

Q28071522-4C651082-C054-4568-A66A-53E3026DBA21

P407

Q28071522-3AAF546F-3F81-49C0-A4A0-9CB299B7CE8A

P478

Q28071522-A5B05A00-CFDC-45E8-97D4-27ED1CBA4F6A

P50

Q28071522-5E3FF3F1-AE27-4C2F-9E67-A5FF1B8F968C

Q28071522-A9960458-7936-44DA-82F8-6E4A4FC7EB0F

Q28071522-C6C3BC2A-A75B-435B-B612-C61AD2E4AA51

P5008

Q28071522-C498D68F-6C27-42B9-8656-A188A48CEBC5

P577

Q28071522-C5CE4D69-061C-4D57-A69D-CA6992CB5CBA

P698

Q28071522-34664F4C-3062-411A-8E9A-D9B9F2CA0D17

P921

Q28071522-9C413E35-C837-4CFA-BF0C-409B382D00A6

P932

Q28071522-4FCFB142-0856-43D7-8F80-EC6AE8776B9B

P3181

P356

WCO.0000000000000289

P1433

Current Opinion in Neurology

P1476

First European consensus for d ...... amilial amyloid polyneuropathy

@en

P2093

David Adams

http://www.w3.org/2001/XMLSchema#string

Ernst Hund

http://www.w3.org/2001/XMLSchema#string

European Network for TTR-FAP (ATTReuNET)

http://www.w3.org/2001/XMLSchema#string

Ivailo Tournev

http://www.w3.org/2001/XMLSchema#string

Josep M Campistol

http://www.w3.org/2001/XMLSchema#string

Michel S Slama

http://www.w3.org/2001/XMLSchema#string

Teresa Coelho

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International

P2860

Synergy of combined doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models

Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade

Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis

Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP

Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial

Mass spectrometric-based proteomic analysis of amyloid neuropathy type in nerve tissue.

Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial

Guideline of transthyretin-related hereditary amyloidosis for clinicians.

Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis.

FAP neuropathy and emerging treatments.

P304

S14-26

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1439259

http://www.w3.org/2001/XMLSchema#string

P356

10.1097/WCO.0000000000000289

http://www.w3.org/2001/XMLSchema#string

P407

P478

29 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P50

Bouke P Hazenberg

P5008

P577

2016-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26734952

http://www.w3.org/2001/XMLSchema#string

P921

P932

4739312

http://www.w3.org/2001/XMLSchema#string